Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Sell
48
MNPR Quote, Financials, Valuation and Earnings
Last price:
$80.49
Seasonality move
:
52.81%
Day range:
$79.50 - $85.01
52-week range:
$20.61 - $105.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.79x
Volume:
105.7K
Avg. volume:
159.4K
1-year change:
282.76%
Market cap:
$537.1M
Revenue:
--
EPS (TTM):
-$3.44
Analysts' Opinion
-
Consensus RatingMonopar Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $111.77, Monopar Therapeutics, Inc. has an estimated upside of 39.05% from its current price of $80.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $93.00 representing 100% downside risk from its current price of $80.38.
Fair Value
-
According to the consensus of 10 analysts, Monopar Therapeutics, Inc. has 39.05% upside to fair value with a price target of $111.77 per share.
MNPR vs. S&P 500
-
Over the past 5 trading days, Monopar Therapeutics, Inc. has underperformed the S&P 500 by -7.02% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Monopar Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Monopar Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Monopar Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Monopar Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Monopar Therapeutics, Inc. reported earnings per share of -$0.48.
Enterprise value:
393.5M
EV / Invested capital:
2.78x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.32x
EV / Free cash flow:
-36.34x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-30.42%
Net Income Margin (TTM):
--
Return On Equity:
-31.63%
Return On Invested Capital:
-31.61%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$9.8M | -$7M | -$21.6M | -$1.6M | -$4.1M | |
| EBITDA | -$9.8M | -$7M | -$21.6M | -$1.6M | -$4.1M | |
| Diluted EPS | -$3.56 | -$1.98 | -$3.44 | -$0.37 | -$0.48 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $22.4M | $14.4M | $8.6M | $6.1M | $144.1M | |
| Total Assets | $22.5M | $14.4M | $8.6M | $6.1M | $144.2M | |
| Current Liabilities | $1.2M | $1.9M | $2M | $1.1M | $2.6M | |
| Total Liabilities | $1.2M | $1.9M | $2M | $1.1M | $2.6M | |
| Total Equity | $21.3M | $12.5M | $6.6M | $4.9M | $141.6M | |
| Total Debt | -- | $20.8K | -- | -- | $70.9K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.6M | -$6M | -$10.8M | -$1.1M | -$2.1M | |
| Cash From Investing | -$3M | $3M | -$15.6M | $985.7K | -$2.1M | |
| Cash From Financing | $1.8M | $3.5M | $148.1M | -$16.5K | $92.4M | |
| Free Cash Flow | -$7.6M | -$6M | -$10.8M | -$1.1M | -$2.1M | |
MNPR
Sector
Market Cap
$537.1M
$28.5M
Price % of 52-Week High
76.55%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-27.38%
-1.33%
1-Year Price Total Return
282.76%
-20.32%
Beta (5-Year)
1.456
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$82.26
200-day SMA
Buy
Level
$50.31
Bollinger Bands (100)
Buy
Level
41.98 - 87.26
Chaikin Money Flow
Sell
Level
-26.2M
20-day SMA
Sell
Level
$83.02
Relative Strength Index (RSI14)
Sell
Level
47.21
ADX Line
Buy
Level
12.57
Williams %R
Neutral
Level
-75.9245
50-day SMA
Sell
Level
$85.12
MACD (12, 26)
Sell
Level
-0.38
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
147.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (13.782)
Sell
CA Score
(Annual)
Level (-0.8006)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.2981)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Stock Forecast FAQ
In the current month, MNPR has received 10 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MNPR average analyst price target in the past 3 months is $111.77.
-
Where Will Monopar Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Monopar Therapeutics, Inc. share price will rise to $111.77 per share over the next 12 months.
-
What Do Analysts Say About Monopar Therapeutics, Inc.?
Analysts are divided on their view about Monopar Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Monopar Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $93.00.
-
What Is Monopar Therapeutics, Inc.'s Price Target?
The price target for Monopar Therapeutics, Inc. over the next 1-year time period is forecast to be $111.77 according to 10 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MNPR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Monopar Therapeutics, Inc. is a Buy. 10 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MNPR?
You can purchase shares of Monopar Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Monopar Therapeutics, Inc. shares.
-
What Is The Monopar Therapeutics, Inc. Share Price Today?
Monopar Therapeutics, Inc. was last trading at $80.49 per share. This represents the most recent stock quote for Monopar Therapeutics, Inc.. Yesterday, Monopar Therapeutics, Inc. closed at $80.38 per share.
-
How To Buy Monopar Therapeutics, Inc. Stock Online?
In order to purchase Monopar Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MNPR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MNPR
Sector
P/E ratio
--
23.75x
PEG ratio
-0.32x
-0.01x
P/B ratio
3.79x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
MNPR
Sector
Revenue growth
--
4.85%
Earnings growth
-30.26%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.40
-$0.20
Profitability
MNPR
Sector
Profitability FY 2024
--
$3.6M
Return on invested capital
-31.61%
-30.98%
Return on assets
-30.42%
-27.62%
Return on equity
-31.63%
-36.69%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
24
Estimated Next Earnings Date
Feb
12
Balance Sheet
MNPR
Sector
Total cash
$143.7M
$27.2M
Short term investments
$14.4M
$25.7M
Total assets
$60.3M
$79.7M
Long term debt
$70.9K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
